Peter is an experienced life-science industry executive and an executive-in-residence with Pappas Capital, where he leads the firm’s initiatives in translational medicine and provides business development and due diligence support to its venture funds and portfolio companies.
He has over thirty-five years’ experience in the pharmaceutical and biotech industry, spanning all areas of the business from sales to country-level general manager and CEO and companies ranging from multinationals like Abbott and Glaxo to start-up biotechs. As VP and Therapy Area Head at Glaxo Wellcome he led the global introduction of combination HIV therapy that revolutionized HIV treatment and quintupled GW’s global HIV portfolio sales, while keying industry leadership on global access policy. Peter subsequently served as CEO of two private start-up enterprises, a viral vector vaccine company that raised over $80 million in NIH grants, and a specialty pharmaceutical company he led to a strategic transaction and exit.
Peter is a past member of the BIO board, past Chairman of the North Carolina Biosciences Organization (NCBIO), and was a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. He has lived and worked in the US, Greece, the Middle East, Puerto Rico, New Zealand, and London.
He currently serves as an executive-in-residence at Cold Spring Harbor Laboratories. He is a member of the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, and is a member of the Long Island Bioscience Hub External Review Board and the Long Island BioMentor Initiative. He has a BA in history and an MBA from Indiana University.